Background and objective: Cryptogenic organizing pneumonia (COP) is corticosteroid responsive but residual computed tomography (CT) chest changes are often noted. The present study examined clinical and HRCT features of COP in which there was incomplete resolution. Methods: We studied 93 patients with histopathologically confirmed COP and serial HRCT imaging. Clinical features were assessed, and serial CT images were analysed. Uni-and multivariate analyses were performed to determine clinical or imaging factors related to incomplete resolution on CT. Results: Complete resolution on CT imaging was seen in 21/93 patients (23%) and residual abnormalities were seen in 72/93 patients (77%). In univariate analysis, total lesion (P = 0.036), degree of consolidation (P = 0.011), treatment duration (P < 0.001) and singlebreath carbon monoxide diffusing capacity of lung (P = 0.021) were significantly associated with residual imaging abnormalities. In multivariate analysis, extent of consolidation (P = 0.018; odds ratio (OR) = 14.92) and treatment duration (P = 0.011; OR = 1.32) remained as significant factors linked to residual abnormalities. CT images in unresolved COP were akin to fibrotic non-specific interstitial pneumonia (fNSIP) in 53/72 (74%) patients. Conclusion: Clinical, radiological and lung diffusion measurements were related to incomplete resolution on CT after COP. Imaging abnormalities on CT chest generally resembled fNSIP.
INTRODUCTION
Cryptogenic organizing pneumonia (COP) is classified as an idiopathic interstitial pneumonia that is characterized histopathologically by plugs of granulation tissue lying within small airways, alveolar ducts and alveoli, and chronic inflammatory cell infiltration in alveolar walls. 1, 2 Findings on CT chest imaging in COP have been well-characterized and include bilateral patchy areas of consolidation with subpleural and lower lung zone predominance. HRCT changes consist of consolidative areas or nodules distributed along the bronchovascular bundles or along subpleural areas. [3] [4] [5] [6] Patients with COP have a good prognosis with corticosteroid therapy. 1 However, despite this therapy, cases of relapse or progression have been reported. [7] [8] [9] Most patients (73%, 16 of 22 patients) with COP have some residual disease on follow-up CT 10 and in such cases 
SUMMARY AT A GLANCE
In patients with cryptogenic organizing pneumonia, 77% had residual computed tomography (CT) abnormalities on follow-up CT chest, even after corticosteroid treatment. The extent of lung abnormalities, consolidation on CT, diffusion measurements and treatment duration were factors associated with residual CT abnormalities. the lung lesions generally resemble a fibrotic nonspecific interstitial pneumonia (fNSIP) pattern. Moreover, the histopathology of COP is reported as fibrinous exudate in acute fibrinous organizing pneumonia, 11 with fNSIP in fibrosing variant of organizing pneumonia or COP/fNSIP overlap 10, 11 and peribronchiolar granuloma in hypersensitivity pneumonia. 12 In these cases of mixed histopathology, even though COP is predominant, patients may have a different prognosis as compared to typical COP histopathology.
Serial HRCT findings in patients with COP have not been reported. Moreover, it is not known if initial clinical or imaging features may be related to residual abnormalities on later CT imaging. Thus, the principal objectives of our study were: (i) to evaluate the initial clinical and CT imaging features and serial CT changes in incompletely resolved COP; and (ii) to examine initial clinical and imaging features related to incomplete resolution of COP.
METHODS

Patient enrolment
We reviewed surgical lung biopsy (SLBx) files from January 1997 to August 2015 at three tertiary hospitals (Samsung Medical Center, Seoul, Korea; Soonchunghyang University Bucheon Hospital, Bucheon, Korea; and Soonchunhyang University Seoul Hospital, Seoul, Korea) by electronic medical records. We identified 107 patients with a histopathological diagnosis of organizing pneumonia of unknown cause. Among the 107 patients, 14 were excluded due to lack of long-term follow-up; of these 14 patients, no follow-up studies were available in 12 patients and follow-up CT was only available for 1 month in two patients. Thus, a total of 93 patients with COP (Male:Female 38:55, mean age AE SD = 57 AE 9.3 years, range; 28-76 years) were included in the present study. The serial HRCT scans were obtained over the mean follow-up period of 26 AE 38.4 months (median, 7 months; range, 2-155 months).This was a retrospective observational study performed at three different institutions. Institutional Review Board approval was obtained and written informed consent was waived.
Pulmonary function test
Initial pulmonary function test (PFT) data were obtained from 88 patients. Forced spirometry (forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ) and total lung capacity (TLC)) and diffusing capacity of the lung for carbon monoxide (DL CO ) were obtained (SensorMedics Corporation, Yorba Linda, CA, USA). FVC and DL CO were expressed as a percentage of the predicted value based on height, age, sex and ethnic origin. Additionally, arterial oxygen tension at room air (PaO 2 ) was measured at the time of biopsy or when PFT results were obtained. Serial trends in PFT s and PaO 2 at follow-up studies were defined as shown in Appendix S1 in Supplementary Information.
Analyses of thin-section CT findings
Two chest radiologists independently reviewed and analysed all images and reached consensus conclusions. Patterns (consolidation, ground-glass opacity, nodule, reticulation and honeycombing), extent (to the nearest 5%) and distribution of lung abnormalities at the initial and final CT were evaluated.
Clinical outcome of patients
Data obtained included clinical symptoms at the initial presentation, duration of symptoms, interval between symptoms and initial CT acquisition, treatment regimens, duration of treatment, the presence of COP relapse and patient survival. Treatment was as follows: prednisone or prednisolone 0.75 mg/kg/day for 4~8 weeks followed by slow gradual dose tapering down to 5 mg/day with a total duration of therapy for up to 6-9 months. Without relapse, 2 therapy was discontinued. If relapse was present, the above-mentioned therapy was resumed. Relapse of COP was defined as the appearance of new characteristic opacities on chest imaging, with compatible clinical features, after a period of stable or improvement.
In order to clarify the clinical implications of residual lung lesions on follow-up CT, we compared PFT results (including FVC, TLC and DL CO ) between patients who had completely resolved disease and those who had residual lung abnormalities.
RESULTS
Baseline patient details and PFT measurements
The demographic findings of 93 patients with biopsyconfirmed COP are summarized in Table 1 . A total of 85 patients (91%) presented with symptoms at the time of diagnosis and most of them had dyspnoea (65 patients, 70%) with an average duration of 2 months. The mean interval between initial presentation and initial CT scan was 61 days (range, 1-370 days). A total of 66 (71%) patients were nonsmokers, 16 (17%) were ex-smokers (mean duration, 30 pack-years) and 11 (12%) were current smokers (mean duration, 27 pack-years).
The PFT results are also shown in Table 1 . A total of 88 (95%) patients had available serial FVC results (percentage of predicted value) at the time of final CT imaging; there was an interval increase in FVC in 24 (38%) patients, stability in 36 (57%) and an interval decrease in three (5%). Among 53 (57%) patients for whom serial DL CO results were available, 20 (38%) patients had an interval increase, 29 (55%) showed stability and 4 (8%) exhibited an interval decrease in diffusion. Initial PaO 2 results were available in 74 patients, but only 12 patients had follow-up PaO 2 results. Four (33%) showed an interval increase, seven (58%) demonstrated stability and one (8%) exhibited an interval decrease in PaO 2 .
Thin-section CT findings
The frequency of CT findings on the initial and final CT scans is summarized in Table 2 . The two most common patterns of lung abnormality on initial CT scans were ground-glass opacity (92 patients, (99%)) and consolidation (69 patients, (74%)). Abnormities on imaging were along peribronchovascular bundles (49 patients, (53%)) and subpleural lung tissue (25 patients, (27%)). Most abnormalities at initial CT showed lower lung zonal predominance (61 patients, (66%)), compared with upper lung zone predominance in only two patients (2%).
On final CT, 21 (23%) patients had complete resolution of lung parenchymal lesions ( Fig. 1) and 72 (77%) had residual disease (Fig. 2) . The most common CT findings on final follow-up scans were ground-glass opacity (70 patients, (75%)) and reticulation (37 patients, (40%)). Among the 72 patients who had residual disease on follow-up CT, 53 (74%) had a pattern of lung abnormality similar to that of fNSIP, six (8%) had a subacute hypersensitivity pneumonitis pattern, four (6%) had a usual interstitial pneumonia pattern and three (4%) demonstrated a cellular non-specific interstitial pneumonia (NSIP) pattern. The remaining six (8%) patients had a residual COP pattern that continued on follow-up CT imaging.
Inter-observer reliability was acceptable (intraclass correlation coefficients for consolidation, 0.94; for ground-glass opacity 0.90; for nodule or mass, 0.88; for reticulation, 0.67; for total lung extent; 0.84).
Clinical outcomes of patients
A total of 72 (77%) of 93 patients had residual disease on final CT; 10 (14%) of 72 patients had progressive disease after a period of being stable or improved during the serial follow-up studies after corticosteroid therapy. The remaining 62 (86%) patients had residual incompletely resolved or stable parenchymal lesions. Of the ten patients with relapse, one died of progressive COP and nine were alive with residual disease.
Of the 93 patients, 74 (80%) were managed as outlined and 5 (5%) received no treatment. For the remaining 14 (15%) patients, the details of management could not be obtained. The mean treatment duration was 8 months (range, 0.3-48 months).
There were four (4%) deaths among 93 patients; one died of COP progression and three died of other causes (two from pneumonia and one due to recurrence of an underlying malignancy, subglottic cancer).
Relationship between residual lung lesions on HRCT and pulmonary function
Clinical features, initial CT findings, and pulmonary function results were compared between patients with complete resolution and residual disease (Table S1 (Supplementary Information)). The overall extent of COP and the extent of consolidation differed significantly between the two groups (patients with complete resolution (n = 21) and with remaining disease (n = 72)). The initial DL CO (percentage of predicted value) in patients with complete resolution were significantly higher than in patients with residual disease. Treatment duration for patients with remaining disease was longer than in patients with complete resolution. Multivariate regression analysis, with adjustment for demographic characteristics, follow-up interval and COP severity showed that the extent of consolidation (P = 0.018, OR (odds ratio) = 14.92, 95% CI: (1.591, 139.910)) and treatment duration (P = 0.011, OR = 1.32, 95% CI: (1.066, 1.629)) were independently associated with residual disease (Table 3) .
DISCUSSION
We assessed lung abnormality in COP on initial HRCT and on subsequent chest CT. The overall extent of lung abnormalities and the degree of consolidation on initial HRCT were significantly related to residual parenchymal disease.
Lee et al. 13 found that the area of consolidation on initial CT in COP was associated with partial or complete resolution of parenchymal abnormalities, whereas reticular opacity was related to persistent or progressive disease in 26 patients. However, in our current study, the presence (22 of 93, 24%) or extent (2% of lung volume) of reticulation did not appear to be a statistically significant factor in predicting remaining disease. The extent of consolidation on initial HRCT scans appeared to be a predictor of residual lung parenchymal disease at follow-up in our cohort. The difference between our findings and those from Lee et al. 13 may be explained by the fact that the previous study was small whereas the current study included a higher number of cases with biopsy-proven COP. Furthermore, our study included mainly those who had not been treated prior to their presentation at each hospital. Our findings on disease relapse are described in Supplementary Appendix S2.
It is known that histopathologically separating COP from NSIP is potentially difficult. 14 Furthermore, according to a histopathological report, 10 histologic COP coexisted with fNSIP in 21 of 31 (68%) patients. Similarly, it is also hard to distinguish between treated and residual COP and fNSIP with CT findings. When patients have histopathologically both COP and fNSIP components (fibrosing variant of COP or fibrosing organizing pneumonia), 10, 12 HRCT may show parenchymal opacity (consolidation plus ground-glass opacity) and variable reticular abnormalities. 9, 15 It is not clear whether such fibrosing variants of COP represents the original manifestation of ongoing idiopathic interstitial pneumonias at presentation or incompletely treated COP. This pattern of fibrosing-variant COP may also be seen in patients with underlying polymyositis or antisynthetase syndrome. 11, 16 DL CO was found to be a predictive factor for the presence of residual lung lesions. Several investigators have suggested that PFT result(s) are related to relapse or residual disease in COP patients. 8, 15, 17 Our previous study 15 reported that initial FVC and DL CO values are the potential predictors of completely resolved disease. In one study, 8 FVC and PaO 2 /FiO 2 (fraction of inspired show a markedly decreased extent of abnormality, but remaining parenchymal abnormalities. Total extent of remaining lung lesions was 25% (ground-glass opacity, 20%; reticulation, 5%). Residual abnormalities resemble fibrotic non-specific interstitial pneumonia. oxygen) levels at presentation are reported as significant predictive findings for the relapse in COP patients. Treatment duration was also a related factor for residual lung lesions. Thus, patients having persistent disease for a long period of time or recurrent disease may need a longer treatment period.
The present study has several limitations. First, the study design was retrospective and some data for the PFT results and interval follow-up CT scans were missing. Second, we included only patients with histopathologically confirmed COP. Therefore, patients having favourable response to corticosteroid therapy might have been excluded owing to no follow-up. This could have resulted in selection bias and a failure to evaluate disease progression over time. Third, follow-up periods varied and the shortest follow-up interval was 2 months (median, 7 months; range, 2-155 months), which may have affected relapse data. Fourth, SLBx specimens were obtained only in one lobe (site) in 62 of 93(67%) patients. Multi-lobe SLBx may have allowed us to exclude if there have been any patients with mixed histopathology such as fibrosing variant of COP, acute fibrious and organizing pneumonia or coexistent COP and hypersensitivity pneumonitis. Fifth, histopathologically analysis of residual disease, simulating fNSIP, could not be performed.
In conclusion, although COP is a disease generally associated with good prognoses, the majority of patients (77%) manifested features of residual disease on subsequent CT chest imaging. When lung abnormalities remain, they largely mimic an fNSIP pattern.
